Literature DB >> 25681012

Nanoparticle mediated silencing of DNA repair sensitizes pediatric brain tumor cells to γ-irradiation.

Forrest M Kievit1, Zachary R Stephen2, Kui Wang2, Christopher J Dayringer2, Jonathan G Sham3, Richard G Ellenbogen4, John R Silber1, Miqin Zhang5.   

Abstract

Medulloblastoma (MB) and ependymoma (EP) are the most common pediatric brain tumors, afflicting 3000 children annually. Radiotherapy (RT) is an integral component in the treatment of these tumors; however, the improvement in survival is often accompanied by radiation-induced adverse developmental and psychosocial sequelae. Therefore, there is an urgent need to develop strategies that can increase the sensitivity of brain tumors cells to RT while sparing adjacent healthy brain tissue. Apurinic endonuclease 1 (Ape1), an enzyme in the base excision repair pathway, has been implicated in radiation resistance in cancer. Pharmacological and specificity limitations inherent to small molecule inhibitors of Ape1 have hindered their clinical development. Here we report on a nanoparticle (NP) based siRNA delivery vehicle for knocking down Ape1 expression and sensitizing pediatric brain tumor cells to RT. The NP comprises a superparamagnetic iron oxide core coated with a biocompatible, biodegradable coating of chitosan, polyethylene glycol (PEG), and polyethyleneimine (PEI) that is able to bind and protect siRNA from degradation and to deliver siRNA to the perinuclear region of target cells. NPs loaded with siRNA against Ape1 (NP:siApe1) knocked down Ape1 expression over 75% in MB and EP cells, and reduced Ape1 activity by 80%. This reduction in Ape1 activity correlated with increased DNA damage post-irradiation, which resulted in decreased cell survival in clonogenic assays. The sensitization was specific to therapies generating abasic lesions as evidenced by NP:siRNA not increasing sensitivity to paclitaxel, a microtubule disrupting agent. Our results indicate NP-mediated delivery of siApe1 is a promising strategy for circumventing pediatric brain tumor resistance to RT.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ape1; Base excision repair; Ependymoma; Medulloblastoma; Nanomedicine; siRNA

Mesh:

Substances:

Year:  2015        PMID: 25681012      PMCID: PMC4439369          DOI: 10.1016/j.molonc.2015.01.006

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  49 in total

1.  Clustered DNA damages induced in isolated DNA and in human cells by low doses of ionizing radiation.

Authors:  B M Sutherland; P V Bennett; O Sidorkina; J Laval
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

3.  Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma.

Authors:  Michael S Bobola; Pawel P Jankowski; Mary E Gross; Jeffery Schwartz; Laura S Finn; A Blank; Richard G Ellenbogen; John R Silber
Journal:  Int J Cancer       Date:  2011-05-05       Impact factor: 7.396

Review 4.  Repair of oxidative damage to DNA: enzymology and biology.

Authors:  B Demple; L Harrison
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

Review 5.  RNA interference in the clinic: challenges and future directions.

Authors:  Chad V Pecot; George A Calin; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2010-12-16       Impact factor: 60.716

6.  Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors.

Authors:  Ajay Srinivasan; Lirong Wang; Cari J Cline; Zhaojun Xie; Robert W Sobol; Xiang-Qun Xie; Barry Gold
Journal:  Biochemistry       Date:  2012-07-24       Impact factor: 3.162

Review 7.  Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer.

Authors:  Rachel Abbotts; Srinivasan Madhusudan
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

8.  Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin.

Authors:  Susan A Lyons; Jeffrey O'Neal; Harald Sontheimer
Journal:  Glia       Date:  2002-08       Impact factor: 7.452

9.  Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci.

Authors:  Mandana Veiseh; Patrik Gabikian; S-Bahram Bahrami; Omid Veiseh; Miqin Zhang; Robert C Hackman; Ali C Ravanpay; Mark R Stroud; Yumiko Kusuma; Stacey J Hansen; Deborah Kwok; Nina M Munoz; Raymond W Sze; William M Grady; Norman M Greenberg; Richard G Ellenbogen; James M Olson
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

Review 10.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

View more
  23 in total

Review 1.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

2.  Theranostic Nanoparticles for RNA-Based Cancer Treatment.

Authors:  Richard A Revia; Zachary R Stephen; Miqin Zhang
Journal:  Acc Chem Res       Date:  2019-05-28       Impact factor: 22.384

3.  Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma.

Authors:  Forrest M Kievit; Kui Wang; Tatsuya Ozawa; Aria W Tarudji; John R Silber; Eric C Holland; Richard G Ellenbogen; Miqin Zhang
Journal:  Nanomedicine       Date:  2017-06-11       Impact factor: 5.307

Review 4.  Medulloblastoma and the DNA Damage Response.

Authors:  Leon F McSwain; Kiran K Parwani; Shubin W Shahab; Dolores Hambardzumyan; Tobey J MacDonald; Jennifer M Spangle; Anna Marie Kenney
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

5.  Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances.

Authors:  Richard A Revia; Miqin Zhang
Journal:  Mater Today (Kidlington)       Date:  2016-04       Impact factor: 31.041

Review 6.  Magnetic Nanoparticles in Cancer Therapy and Diagnosis.

Authors:  Ali Farzin; Seyed Alireza Etesami; Jacob Quint; Adnan Memic; Ali Tamayol
Journal:  Adv Healthc Mater       Date:  2020-03-20       Impact factor: 9.933

7.  Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.

Authors:  Kui Wang; Forrest M Kievit; Jonathan G Sham; Mike Jeon; Zachary R Stephen; Arvind Bakthavatsalam; James O Park; Miqin Zhang
Journal:  Small       Date:  2015-12-07       Impact factor: 13.281

8.  Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.

Authors:  Duhyeong Hwang; Taylor Dismuke; Andrey Tikunov; Elias P Rosen; John R Kagel; Jacob D Ramsey; Chaemin Lim; William Zamboni; Alexander V Kabanov; Timothy R Gershon; Marina Sokolsky-Papkov PhD
Journal:  Nanomedicine       Date:  2020-11-28       Impact factor: 5.307

Review 9.  Use of Super Paramagnetic Iron Oxide Nanoparticles as Drug Carriers in Brain and Ear: State of the Art and Challenges.

Authors:  Caroline Guigou; Alain Lalande; Nadine Millot; Karim Belharet; Alexis Bozorg Grayeli
Journal:  Brain Sci       Date:  2021-03-11

10.  Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities.

Authors:  Guanyou Lin; Richard A Revia; Miqin Zhang
Journal:  Adv Funct Mater       Date:  2020-10-13       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.